2024-11-02 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company. Its stock has significantly underperformed the S&P 500 (VOO) over the given period. 

* **JNJ Cumulative Return:** 33.41%
* **VOO Cumulative Return:** 131.38%
* **Relative Underperformance:** -97.97% 
* **Relative Underperformance Rank:**  6.5 (meaning its performance is in the 6.5th percentile of its historical range compared to VOO)

**2. Recent Price Movement:**

* **Last Price:** 159.86 (Last-market: 160.63)
* **5-Day Moving Average:** 160.61
* **20-Day Moving Average:** 162.03
* **60-Day Moving Average:** 162.72

JNJ is currently trading slightly below its 5-day moving average and further below its 20-day and 60-day moving averages, indicating a potential short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 45.42 (Neutral): The RSI is in neutral territory, indicating neither overbought nor oversold conditions.
* **PPO:** -0.22 (Bearish): The PPO is negative, suggesting potential bearish momentum.
* **Delta_Previous_Relative_Divergence:** -0.76 (Down):  The recent 20-day relative divergence suggests a short-term downtrend.
* **Expected Return:** 0.0%  (Long-Term):  Despite the current underperformance, the expected return for JNJ is 0% for long-term (2 years+) accumulation, suggesting potential alignment with the S&P 500's long-term growth.

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Revenue       |
|-------------|-------|----------------|
| 2024-10-23 | 1.12  | $22.47 B      |
| 2024-07-25 | 1.95  | $22.45 B      |
| 2024-05-01 | 1.35  | $21.38 B      |
| 2024-02-16 | 1.68  | $21.39 B      |
| 2023-10-27 | 10.32 | $21.35 B      |

JNJ's recent earnings have been mixed, with some quarters exceeding expectations and others falling short. The latest earnings report for the quarter ending 2024-10-23 showed a decrease in EPS compared to the previous quarter. However, revenue remained relatively stable. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2024-09-30  | $22.47B | 69.01%       |
| 2024-06-30  | $22.45B | 69.40%       |
| 2024-03-31  | $21.38B | 69.55%       |
| 2023-12-31  | $21.39B | 68.23%       |
| 2023-09-30  | $21.35B | 69.06%       |

JNJ demonstrates a strong and consistent profitability, with a high and steady profit margin over the past several quarters. This stability suggests a resilient business model.

**2) Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2024-09-30  | $70.16B | 3.84%   |
| 2024-06-30  | $71.54B | 6.55%   |
| 2024-03-31  | $70.02B | 4.65%   |
| 2023-12-31  | $68.77B | 5.89%   |
| 2023-09-30  | $71.23B | 36.54%  |

The ROE demonstrates some volatility, suggesting potential changes in capital efficiency or strategic investments.  It is important to note that the high ROE in Q3 2023 could be due to a one-time event and is not necessarily indicative of sustained performance. 

**6. News and Recent Developments:**

* **Recent Earnings Releases:**  A review of recent earnings news on platforms like Shacknews and others will provide the most up-to-date information on recent earnings calls and any significant announcements related to JNJ's performance.
* **Market Outlook:** Analyze recent market outlooks for JNJ from various sources like Finbold, SeekingAlpha, and reputable financial news outlets. This will give you an overview of market analysts' predictions and general sentiment regarding the stock's future performance. 
* **Analyst Opinions:**  Check analyst ratings and price targets for JNJ on platforms like Yahoo Finance, MarketBeat, or TipRanks. Look for consensus ratings and significant changes in analysts' opinions over time.
* **Performance Highlights:**  Pay attention to any significant events that may have impacted JNJ's stock price recently, such as regulatory approvals, product launches, partnerships, or legal settlements.

**7.  Overall Analysis:**

JNJ's stock has significantly underperformed the S&P 500 in the past. This is likely due to a combination of factors, including:

* **Competition:** JNJ faces increasing competition in its core business segments, particularly in pharmaceuticals and medical devices.
* **Regulatory Pressure:** The pharmaceutical industry is subject to intense regulatory scrutiny, which can impact JNJ's profitability.
* **Market Sentiment:** JNJ may be facing headwinds due to negative market sentiment, such as concerns about rising interest rates and inflation.

However, despite the recent underperformance, JNJ remains a financially stable and profitable company with a strong track record. The company's diversified portfolio, strong brands, and focus on innovation offer some potential for future growth. 

**Investment Recommendations:**

While JNJ's short-term outlook is unclear, investors with a long-term horizon may find it attractive for accumulation due to its:

* **High Profitability:** JNJ consistently generates strong profits, indicating a resilient business model.
* **Diversification:** The company's diverse product portfolio reduces its exposure to specific market risks.
* **Strong Brand Recognition:**  JNJ's brand recognition and established market position provide it with a competitive advantage.

It is essential to conduct thorough research and consult with a financial advisor before making any investment decisions. Consider your risk tolerance, investment goals, and the broader market conditions before investing in JNJ.
